| You are here: Home: BCU 4|2004: C Kent Osborne, MD: Select publications
Select publications
Baum M etal. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract
Bharwani L etal. Inhibiting the EGFR/HER2 pathway with gefitinib and/or trastuzumab restores tamoxifen sensitivity in HER2-overexpressing tumors. Breast Cancer ResTreat 2003; Abstract 25.
Boccardo F etal. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer ResTreat 2003;82(Suppl 1); Abstract 3.
Dowsett M, on behalf of the ATACTrialists'Group. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer ResTreat 2003; Abstract 4.
Ellis MJ etal. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808-16. Abstract
Goss PE etal. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl JMed 2003;349(19):1793-802. Abstract
Love RR etal. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002;20(10):2559-66. Abstract
Osborne CKetal. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract
Osborne CKet al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95(5):353-61. Abstract
Robertson JF etal. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract
Smith I, Dowsett M, on behalf of the IMPACT Trialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer ResTreat 2003; Abstract 1.
|
